Skip to main content
Premium Trial:

Request an Annual Quote

Cynthia Collins

Cynthia Collins has joined the board of directors of Editas Medicine. Most recently, she was the CEO of Human Longevity. Prior to that, she was CEO/GM of General Electric's Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. Before that, she was president and CEO of GenVec, and prior to that, group vice president of the Cellular Analysis Business of Beckman Coulter. Collins holds a BS degree in microbiology from the University of Illinois, Urbana, and an MBA from the University of Chicago Booth School of Business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.